Form 4: Cassava Sciences SVP & General Counsel, Robert Christopher Cook, Granted Stock Options

Robert Christopher Cook, SVP & General Counsel of Cassava Sciences, was granted stock options for 10,000 shares on May 20, 2024.

Summary

• Robert Christopher Cook, the SVP & General Counsel of Cassava Sciences, was granted stock options on May 20, 2024.
• The stock options are for 10,000 shares of Cassava Sciences common stock.
• The exercise price of the options is $22.10 per share.
• The options vest over four years, at a rate of 1/48th each full month, and expire on May 20, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance. It aligns executive interests with shareholders.

Positives

• The granting of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule of four years is typical for such grants.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes management to increase shareholder value.
• The executive benefits from the potential upside of the stock options.

Key Dates